FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER, PHASE 1 CLINICAL STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ANTI SIGLEC-15 PYX-106 IN SUBJECTS WITH ADVANCED SOLID TUMORS

Authors
Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2023
This article has no abstract
Epistemonikos ID: 585b288cab8e0b422e2e5847d9f64adc304b772f
First added on: Feb 17, 2025